Archive for Stock Market News

Emerging SARS-COv-2 Variant Is Revenue Growth Opportunity for Vaccine Developer

Source: Streetwise Reports   11/30/2021

Just a few days after the WHO deemed the COVID-19 Omicron variant a serious global health concern, leading mRNA-based vaccine developers BioNTech and Pfizer, along with rival Moderna, advised that if needed, the companies would be capable of developing a vaccine for the new mutating strains within roughly 100 days. H.C. Wainwright & Co. commented in a research note that it reiterates its “Buy” rating for BioNTech SE.

COVID-19 Omicron variant covid covid19

In a November 29 research note, H.C. Wainwright & Co. LLC Healthcare Analysts Robert Burns and Raghuram Selvaraju, Ph.D. commented that as the novel SARSCoV-2 Omicron variant spreads, biotechnology company BioNTech SE’s (BNTX:NASDAQ) development partner Pfizer Inc. (PFE:NYSE) claimed that “it could produce a tailor-made vaccine in roughly 100 days.”

The H.C. Wainwright & Co. report mentioned that within the last couple of days, the World Health Organization (WHO) officially designated Omicron (B.1.1.529) as a variant of concern (VOC). Since the WHO made its announcement, the Omicron variant has been detected in several additional countries.

The analysts stated that at present only a limited amount of scientific data is available regarding the Omicron variant’s transmissibility, disease severity and the effectiveness of existing vaccines in combating the new strain. The WHO reported that it suspects that mutation occurring within Omicron may carry the potential to increase transmission and disease severity.

H.C. Wainwright commented that, “preliminary evidence suggests an increased risk of reinfection with this variant.” The research firm added that with the rising concern associated with Omicron, BioNTech expects that it will receive the lab test results for the Omicron variant within two weeks.

The report noted that if the new data gathered for Omicron demonstrates significantly lower vaccine efficacy or resistance to existing vaccines, BioNTech and its partner Pfizer, as well as Moderna Inc. (MRNA:NASDAQ), believe that they would be able to develop a targeted vaccine for use against Omicron within about 100 days.

H.C. Wainwright advised that if this scenario were to occur, then it anticipates that the resulting increased demand for new or updated vaccines would have positive impact on BioNTech’s top-line revenue. The analysts commented that they expect the Omicron strain is highly likely to continue its global spread over the coming weeks. H.C. Wainwright stated that it believes that mRNA-based vaccines such as Pfizer/BioNTech’s would be more amenable to adaptations to confront new emerging virus strains compared to peptide- or protein-based vaccines.

The report pointed out that late last week, Pfizer and BioNTech announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) had issued a positive opinion for COMIRNATY vaccine deployment for children from ages five to eleven years old. H.C. Wainwright advised that it is expected that the European Commission (EC) will issue a final decision on a variation to the Conditional Marketing Authorization (CMA) very soon.

The analysts explained that positive data collected in a Phase 2/3 clinical study offer strong support for a positive ruling by the EC. The report mentioned that in the referenced study, “two doses of COMIRNATY 10μg administered 21 days apart resulted in a vaccine efficacy rate of 90.7% in participants without prior SARSCoV-2 infection, measured from 7 days after the second dose, during a period when Delta was the prevalent strain.”

H.C. Wainwright also advised that earlier this month, the FDA amended the COMIRNATY’s booster dose Emergency Use Authorization (EUA) and approved the booster shot for adults 18 years of age or older. The report listed that the expanded EUA was authorized based upon a randomized Phase 3 trial of more than 10,000 individuals who were administered a 30μg COMIRNATY booster dose.

Importantly, the top-line data from this study applied to participants that were given a booster and previously had completed the two-dose series of COMIRNATY vaccine and that testing was performed at a time when the Delta variant was the prevalent strain. The analysts indicated that in the study, the COMIRNATY booster group demonstrated vaccine efficacy of 95.6%.

H.C. Wainwright stated that from its perspective, broad-based booster deployment is an important key step in the process of achieving and maintaining herd immunity and is an integral part of COMIRNATY’s long-term commercial success.

The analysts advised that their valuation methodology for BioNTech is based upon a tiered discounted cash flow (DCF) model employing a 9% discount rate, 3% terminal growth rate and 31% projected effective tax rate. Using these metrics results in a market value of approximately $88.7 billion, or $360/share based on an estimated 246.5 million shares outstanding at the end of Q3/22.

H.C. Wainwright & Co. LLC stated that it is reiterating its “Buy” rating and 12-month price target of $360/share for BioNTech SE. The company’s American Depository Receipt (ADR) shares trade on the Nasdaq Exchange under the symbol “BNTX” and last closed for trading at $362.50 on Monday, November 29, 2021.

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of ?????, a company mentioned in this article.

6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Important Disclaimers for H.C. WAINWRIGHT & Co., BioNTech SE, Nov. 29, 2021

Investment Banking Services include, but are not limited to, acting as a manager/co-manager in the underwriting or placement of securities, acting as financial advisor, and/or providing corporate finance or capital markets-related services to a company or one of its affiliates or subsidiaries within the past 12 months.

H.C. Wainwright & Co, LLC (the “Firm”) is a member of FINRA and SIPC and a registered U.S. Broker-Dealer.

I, Robert Burns and Raghuram Selvaraju, Ph.D. , certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies.

A research analyst of the firm and/or the research analyst’s household has a financial interest in and own the securities of BioNTech SE (including, without limitation, any option, right, warrant, future, long or short position).

As of October 31, 2021 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of BioNTech SE.

Neither the research analyst nor the Firm knows or has reason to know of any other material conflict of interest at the time of publication of this research report.

The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services.

The Firm or its affiliates did not receive compensation from BioNTech SE for investment banking services within 12 months before, but will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report.

The Firm does not make a market in BioNTech SE as of the date of this research report.

The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. Past performance is no guarantee of future results. This report is offered for informational purposes only, and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. This research report is not intended to provide tax advice or to be used to provide tax advice to any person. Electronic versions of H.C. Wainwright & Co., LLC research reports are made available to all clients simultaneously.

H.C. Wainwright & Co., LLC does not provide individually tailored investment advice in research reports. This research report is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation, and the particular needs of any specific person. Investors should seek financial advice regarding the appropriateness of investing in financial instruments and implementing investment strategies discussed or recommended in this research report.

H.C. Wainwright & Co., LLC’s and its affiliates’ salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies that reflect opinions that are contrary to the opinions expressed in this research report.

H.C. Wainwright & Co., LLC and its affiliates, officers, directors, and employees, excluding its analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this research report.

The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data on the company, industry or security discussed in the report. All opinions and estimates included in this report constitute the analyst’s judgment as of the date of this report and are subject to change without notice.

Securities and other financial instruments discussed in this research report: may lose value; are not insured by the Federal Deposit Insurance Corporation; and are subject to investment risks, including possible loss of the principal amount invested.

AI Vision Semiconductor Firm Posts 64% Increase in YoY Revenue Sending Shares Higher

Source: Streetwise Reports   12/01/2021

Ambarella Inc. shares traded nearly 20% higher after the company reported Q3/22 financial results that included a 64% increase in YoY revenue together with higher gross margins.

Artificial Intelligence

After U.S. markets closed for trading yesterday afternoon, AI vision
silicon company Ambarella Inc. (AMBA:NASDAQ), which is focused on developing low-power system-on-a-chip (SoC) semiconductors, artificial intelligence (AI) and image signal processing and high-resolution video compression announced financial results for the third quarter of 2022 ended Oct. 31, 2021.

Ambarella reported that revenue in Q3/22 increased 64% to $92.2 million, compared to $56.1 million in Q3/21. The company added that during the nine months ended Oct. 31, 2021, revenues totaled $241.6 million, which it said represented a 50% increase over the $160.8 million achieved during the comparable nine-month period in the prior fiscal year.

The firm indicated that GAAP gross margin in Q3/22 improved to 62.5%, versus 62.0% in Q3/21. Similarly, during the first nine months of FY/22, GAAP gross margin increased to 62.4%, versus 60.8% recorded during the same nine-month period in FY/21.

Ambarella advised that for Q3/22, it posted a GAAP net profit in the amount of $0.8 million, or $0.02 per diluted share, versus a GAAP net loss of $17.1 million, or a loss of $0.49 per diluted share in Q3/21. For the first nine-month period in FY/22, the company stated that it registered a GAAP net loss of $17.2 million, or loss of $0.47 per diluted share, compared to a GAAP net loss of $47.3 million, or a loss of $1.37 per diluted share during the first nine months of FY/21.

The company mentioned that on a non-GAAP, gross margin in Q3/22 came in at 63.1%, compared to 62.7% in Q3/21. During the same corresponding period, the firm listed that non-GAAP net income was $22.2 million, or $0.57 per diluted ordinary share, compared to $3.3 million, or $0.09 per diluted ordinary share in the prior year’s quarter.

Ambarella highlighted that it completed its acquisition of Oculii Corp. on Nov. 5, 2021, and that those operations will be incorporated into the company’s Q4/22 and FY/22 financial results.

The company offered some forward revenue and expense guidance and advised that for Q4/22 it expects that revenue will be in the range of between $88.5 and $91.5 million. The firm said that on a non-GAAP basis, it anticipates a gross margin of 63% to 64% and operating expenses of between $39 and $41 million.

The company mentioned that at the end of Q3/22 on Oct. 31, 2021, it had total cash and other highly liquid assets of $457.8 million on its balance sheet, versus $423.6 million at the end of Q3/21. The firm noted that on Nov. 5, 2021, it completed its purchase of Oculii using $307.5 million of cash held on its balance sheet to finance the transaction.

Ambarella’s President and CEO Fermi Wang commented, “Our transformation into a deep learning AIoT processing company took another leap forward with the acquisition of Oculii, a provider of advanced algorithms for high definition imaging radars. The radar perception market is incremental, but most importantly this transaction feeds into our long-term strategy to provide a more comprehensive AIoT processor to our customers.”

“I’m pleased with our progress in Q3, with positive operating leverage driving non-GAAP operating margins into the 20% range. Our operational execution remains strong, yet supply dynamics remain difficult to predict, as shortages of other companies’ components has become a more significant and gating factor to our results and outlook,” Wang added.

Ambarella is headquartered in Santa Clara, Calif., and is a developer of low-power SoC semiconductors that are utilized in AI processing, advanced image signal processing and high-resolution video compression. The firm listed that its products are integrated into a broad spectrum of human and computer vision applications, such as advanced driver assistance systems, driver and autonomous recording and monitoring, video security, robotics and other AI areas. The company stated that “its low-power system-on-chips (SoCs) offer high-resolution video compression, advanced image processing, and powerful deep neural network processing to enable intelligent cameras to extract valuable data from high-resolution video streams.”

Ambarella started the day with a market cap of around $6.6 billion with approximately 36.66 million shares outstanding and a short interest of about 3.7%. AMBA shares opened nearly 15% higher today at $206.10 (+$26.58, +14.81%) over yesterday’s $179.52 closing price and reached a new 52-week high price this morning of $227.5899. The stock has traded today between $203.2301 and $227.5899 per share and is currently trading at $213.30 (+$33.78, +18.82%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.

Omicron COVID Variant-Possible Strong Rally-INDU & TRAN

By TheTechnicalTraders 

– As we’ve been watching the markets recoil away from risks related to the new Omicron COVID variant and other factors, one simple thought keeps running through my head. What if the markets suddenly shift away from this panic selling and resume a rally/recovery trend – possibly pushing to new all-time highs before the end of the year?

Recently, the Put/Call ratio reached a moderate-high near 0.84. I interpret this as long traders buying protection in the event of an extended breakdown in the US/global markets. In the past, typically, when the Put/Call ratio reaches levels above 0.80 – the markets are very close to a bottom.

Prior Downside GAPS Setup A Potential Rip-Your-Face-Off Rally

Next, I noticed the GAP in price on the Dow Jones Industrial Average and the Transportation Index. That got me thinking, “a sudden reversal in price, possibly resulting in a series of price squeeze events, may prompt a strong rally phase back above the GAP levels.” If this happens, we may see a 5% to 7% rally in the US markets take place to restart the Santa Rally phase.

INDU Gap Near $35,600 May Become A Clear Upside Target

This Daily INDU chart shows the GAP I’m talking about and shows what I expect may happen if the markets shake off the Omicron fears and get back into bullish trending mode.  It won’t take much to drive the INDU 7% higher from recent lows if fear subsides and traders pile into long positions expecting Q4:2021 to be strong and the Santa Rally to kick in.

TRAN Gap Near $16,800 May Provide Additional Confirmation Of A Bullish Rally Phase

This Daily TRAN chart shows a similar GAP in price that could also trigger a big rally towards new all-time highs if the markets suddenly shift gears. The fear that settled over the global markets because of the Omicron virus strain may have pushed the markets into a fairly deep pullback. As we’ve seen repeatedly, when these pullbacks end, the US markets shift back into strong bullish price trending and often rally to new all-time highs.

This GAP on the TRAN chart may further confirm that the downside price pressure has ended and a new rally phase is setting up for the US markets.

Just a few days ago, I posted a research article showing results from a proprietary data mining utility I use that illustrated the typical bullish market strength in November and December. You can read that article here: Thetechnicaltraders.com.

Sign up for my free trading newsletter so you don’t miss the next opportunity!

I believe the global markets will attempt to move past the fear we’ve seen related to the Omicron virus strain. It is becoming more evident that many nations are already somewhat prepared to deal with it throughout December/January. If there is sudden news that it, or any new virus strain, is far more dangerous, things could change very quickly. But I believe the US markets are searching for support and are very likely to end 2021 at or near new all-time highs – supporting a very strong Santa Rally.

Watch for end-of-day SQUEEZE events to push price levels higher and higher over the next few days – possibly targeting these GAP areas or higher.

Want to learn more about what affects the markets?

Learn how I use specific tools to help me understand price cycles, set-ups, and price target levels. Over the next 12 to 24+ months, I expect very large price swings in the US stock market and other asset classes across the globe. I believe the markets are starting to transition away from the continued central bank support rally phase and may start a revaluation phase as global traders attempt to identify the next big trends. Precious Metals will likely start to act as a proper hedge as caution and concern start to drive traders/investors into Metals.

If you need technically proven trading and investing strategies using ETFs to profit during market rallies and to avoid/profit from market declines, be sure to join me at TEP – Total ETF Portfolio.

Have a great day!

Chris Vermeulen
Chief Market Strategist

TheTechnicalTraders.com

Biopharma Launches COVID Vaccine Program in South Africa & Mexico

Source: Streetwise Reports   11/30/2021

Oramed Pharmaceuticals’ oral vaccine offers “convenience and safety advantages as well as coverage of emergent variant strains,” noted a Nov. 29, 2021 H.C. Wainwright & Co. report.

Coronavirus

New developments regarding Oramed Pharmaceuticals Inc.’s (ORMP:NASDAQ) COVID-19 vaccine are advancing the program outside the U.S., and the company continues making strides in testing its insulin product in types 1 and 2 diabetes, reported H.C. Wainwright & Co. analyst Ram Selvaraju in a Nov. 29 research note.

Also, H.C. Wainwright raised its 12-month price target on Israel-based Oramed to $32 per share from $17 after revising its model assumptions pertaining to the biopharma’s lead drug candidates, ORMD-0801 and ORMD-0901.

Regarding its COVID-19 vaccine, Selvaraju reported that Oramed’s subsidiary, Oravax Medical Inc., is preparing to begin a Phase 1 trial of its oral, virus-like particle vaccine technology in South Africa after recently receiving approval to proceed.

The vaccine “targets three SARS-CoV-2 coronavirus surface proteins, including proteins less susceptible to mutation, thus making the vaccine potentially more effective against current and future variants of the COVID-19 virus,” Selvaraju pointed out.

In addition, Oravax recently formed a 50/50 joint venture with Genomma Lab to develop and commercialize Oravax’s COVID-19 vaccine candidate in Mexico. Based there, Genomma is a pharmaceutical and personal care products firm.

“We believe that there remains ample room for additional vaccine approaches, particularly those that offer both convenience and safety advantages as well as coverage of emergent variant strains, as could be achieved with Oravax,” Selvaraju commented. “The total COVID-19 vaccine market could approach $100 billion in 2022, in our view.”

As for Oramed’s flagship product, an oral insulin capsule, ORMD-0801, the biopharma “continues to achieve key milestones,” Selvaraju reported.

Specifically, the company has enrolled and randomized more than three-quarters of the 675 patients to be included in its most advanced trial, the Phase 3 ORA-D-013-1. The study will continue evaluating ORMD-0801 in type 2 diabetes.

The ORMD-0801 trial consists of two components. One, ORA-D-013-1, taking place at 75 U.S. locations, will test the insulin product in patients who are taking two or three oral glucose-lowering agents.

The second component, ORA-013-2, will test ORMD-0801 in 450 patients, in the U.S., Europe and Israel, who have subpar glycemic control and are either are on a modified diet but no medication or are on Metformin as sole treatment.

As far as a timeline to market for ORMD-0801, Selvaraju outlined that commercial launch could occur in the U.S. and Europe in 2024. Leading up to that, completion of enrollment and data readout should occur for both Phase 3 studies next year. Oramed could apply for a biologics license application for the insulin product in 2023, and the U.S. Food and Drug Administration could approve it in 2024.

Also, Selvaraju noted, H.C. Wainwright expects Oramed to partner on commercialization of ORMD-0801 outside of China.

“Revenue to Oramed derived from sales of ORMD-0801 could thus drive meaningful upside to our forecasts,” he added.

Disclosures:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Important Disclaimers for H.C. Wainwright & Co., Oramed Pharma. Inc., Nov. 29, 2021 
This material is confidential and intended for use by Institutional Accounts as defined in FINRA Rule 4512(c). It may also be privileged or otherwise protected by work product immunity or other legal rules.
H.C. WAINWRIGHT & CO, LLC RATING SYSTEM: H.C. Wainwright employs a three tier rating system for evaluating both the potential return and risk associated with  owning common equity shares of rated firms. The expected return of any given equity is measured on a RELATIVE basis of other companies in the same sector. The price objective is calculated to estimate the potential movements in price that a given equity could reach provided certain targets are met over a defined time horizon.
Price objectives are subject to external factors including industry events and market volatility.

Investment Banking Services include, but are not limited to, acting as a manager/co-manager in the underwriting or placement of securities, acting as financial advisor, and/or providing corporate finance or capital markets-related services to a company or one of its affiliates or subsidiaries within the past 12 months.

H.C. Wainwright & Co, LLC (the “Firm”) is a member of FINRA and SIPC and a registered U.S. Broker-Dealer.

I, Raghuram Selvaraju, Ph.D. , certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies.
A research analyst of the firm and/or the research analyst’s household has a financial interest in and own the securities of BioNTech SE (including, without limitation, any option, right, warrant, future, long or short position).
As of October 31, 2021 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of BioNTech SE.
Neither the research analyst nor the Firm knows or has reason to know of any other material conflict of interest at the time of publication of this research report.
None of the research analysts or the research analyst’s household has a financial interest in the securities of Oramed Pharmaceuticals, Inc. (including, without limitation, any option, right, warrant, future, long or short position).
As of October 31, 2021 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of Oramed Pharmaceuticals, Inc.. Affiliates of H.C. Wainwright beneficially own 1% or more of the common equity securities of Oravax Medical Inc., a joint-venture that is majority-owned by Oramed Pharmaceuticals Inc.
Neither the research analyst nor the Firm knows or has reason to know of any other material conflict of interest at the time of publication of this research report.
The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services.
The firm or its affiliates received compensation from Oramed Pharmaceuticals, Inc. for non-investment banking services in the previous 12 months.
The Firm or its affiliates did not receive compensation from BioNTech SE for investment banking services within twelve months before, but will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report.
The Firm or its affiliates did receive compensation from Oramed Pharmaceuticals, Inc. for investment banking services within twelve months before, and will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report.
H.C. Wainwright & Co., LLC managed or co-managed a public offering of securities for Oramed Pharmaceuticals, Inc. during the past 12 months.
The Firm does not make a market in Oramed Pharmaceuticals, Inc. and BioNTech SE as of the date of this research report. The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. Past performance is no guarantee of future results. This report is offered for informational purposes only, and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. This research report is not intended to provide tax advice or to be used to provide tax advice to any person. Electronic versions of H.C. Wainwright & Co., LLC research reports are made available to all clients simultaneously.
No part of this report may be reproduced in any form without the expressed permission of H.C. Wainwright & Co., LLC. Additional information available upon request.
H.C. Wainwright & Co., LLC does not provide individually tailored investment advice in research reports. This research report is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person. Investors should seek financial advice regarding the appropriateness of investing in financial instruments and implementing investment strategies discussed or recommended in this research report.

H.C. Wainwright & Co., LLC’s and its affiliates’ salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies that reflect opinions that are contrary to the opinions expressed in this research report.
H.C. Wainwright & Co., LLC and its affiliates, officers, directors, and employees, excluding its analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this research report.
The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data on the company, industry or security discussed in the report. All opinions and estimates included in this report constitute the analyst’s judgment as of the date of this report and are subject to change without notice.
Securities and other financial instruments discussed in this research report: may lose value; are not insured by the Federal Deposit Insurance Corporation; and are subject to investment risks, including possible loss of the principal amount invested.

Global Markets-It’s Do-Or-Die Time

By TheTechnicalTraders 

– Almost all of the US and global markets volatility has taken place over the last 6+ trading days. Even though economic data continues to show a strengthening US economy and jobs market, the news of the Omicron COVID variant has spooked the global markets. I’m going to illustrate how the markets are nearing critical support levels that are a “Do-Or-Die” level for the market, in my opinion.

Let’s get right into the charts – shall we?

NASDAQ Support Near $15,721 Should Act As A Solid Floor

This NASDAQ chart highlights the orange support level near $15,271 that I believe will act as a HARD FLOOR/SUPPORT for the US markets. We may see $14,750 become the next downside target level if the NQ falls below this level on strong selling. If this support level holds, then I expect the US markets to resume a rally trend and attempt to target $17,000 or higher before the end of 2021.

Custom US Stock Market Index Confirms Support Near $15,721

This Custom US Stock Market Weekly Chart highlights the key support channel that originates in early 2021 and spans across recent lows (the DARK BLUE LINE). My opinion is that the alignment of the $15,721 support level from the chart above and this key support channel on the Custom US Stock Market Index chart creates a confluence of critical support. This level becomes a “Do-Or-Die” level for the markets to attempt to bottom and recover going forward.

Custom Volatility Index Sets Up A Deep Potential Bottom Level

Lastly, this Weekly Custom Volatility Index chart highlights the multiple deep downside support ranges that have continued to drive future price rallies since the original COVID collapse. The current Custom Volatility Index level is below the last two pullbacks in the US markets and well within the support channel from late 2020 and early 2021.

This Custom Volatility Index would clearly show a breakdown in the US markets by moving below the 6.0 to 6.50 level on strong selling pressure. That is currently not happening, and I suspect the lack of real selling pressure reflects a panic selling mode – not a change in true price trend.

My opinion is the US markets will struggle to hold near recent lows – attempting to hammer out a bottom/base over the next few days. If these critical support levels fail to prompt a bottom in price, we’ll know soon enough. The markets can stay irrational far longer than many people expect.

The next 2 to 5+ trading days should clearly show us if these support levels and channels are solid or not. If the global markets are going to continue to move lower, we should find out soon enough.

Sign up for my free trading newsletter so you don’t miss the next opportunity!

If I’m correct and the markets do hold up near these support channels, we may begin to see a new “Rip-Your-Face-Off” rally phase to start a powerful Santa Rally closing out 2021. That would be incredible to witness and experience.

Watch for support near $15,721 to $15,750 on the NQ over the next 5+ trading days. I believe that level is the “Do-Or-Die” level for the markets going forward.

Curious to Learn More about global markets?

Learn how I use specific tools to help me understand price cycles, set-ups, and price target levels. Over the next 12 to 24+ months, I expect very large price swings in the US stock market and other asset classes across the globe. I believe the markets are beginning to transition away from the continued central bank support rally phase and may start a revaluation phase as global traders attempt to identify the next big trends. Precious Metals will likely begin to act as a proper hedge as caution and concern start to drive traders/investors into Metals.

If you need technically proven trading and investing strategies using ETFs to profit during market rallies and to avoid/profit from market declines, be sure to join me at TEP – Total ETF Portfolio.

Have a great day!

Chris Vermeulen
Chief Market Strategist

TheTechnicalTraders.com

AMZN Triple Zigzag Ending Near 2867.82

By Orbex

Amazon

The current AMZN structure shows a bullish impulse. This includes the formation of a deep fourth wave of the primary degree.

The primary correction wave ④, apparently, takes the form of an intermediate triple combination (W)-(X)-(Y)-(X)-(Z). Let’s pay attention to the last wave (Z), which is not enough to complete the correction pattern.

Wave (Z) most likely takes the form of a triple zigzag W-X-Y-X-Z. The minute ending diagonal could have finished the development of the minor intervening wave X. So, the price could fall in the minor wave Z in the direction of the price level of 2867.82 soon.

At that level, wave Z will be at 161.8% of wave Y.

Then bulls could enter the market and push the price in the primary fifth wave above the level of 3772.99, marked by an intermediate intervening (X), as shown on the chart.

Amazon

However, the formation of the primary correction ④ could have ended. And now the primary fifth wave is developing, taking the form of an ending diagonal (1)-(2)-(3)-(4)-(5) of the intermediate degree.

It seems that correction (4) in the form of a minor double zigzag W-X-Y has come to an end not so long ago. An intermediate wave (5), taking the form of a double zigzag W-X-Y, is currently under construction.

In the near future, market participants can expect the construction of a minute zigzag ⓐ-ⓑ-ⓒ, which forms the final minor wave Y. Growth in this zigzag is possible near 4349.36. At that level, wave ⑤ will be at 76.4% of primary impulse wave ③.


Orbex-LogoArticle by Orbex

Orbex is a fully licensed broker that was established in 2011. Founded with a mission to serve its traders responsibly and provides traders with access to the world’s largest and most liquid financial markets. www.orbex.com

Omicron and market sell-off: don’t be surprised if there’s more turbulence to come

By Arturo Bris, International Institute for Management Development (IMD)

Until the Omicron variant hit the headlines, the signs were that 2021 was going to close with a stellar stock-market performance. Most markets have been on the rise since the beginning of the year, with the S&P500 up about 25% and the FTSE All Share index up by about 10%.

There had certainly been some concern that share valuations were irrationally high. This concern was justified – especially if we take into account that most markets closed 2020 on a positive note, too. Having experienced the worst pandemic in 100 years, and also a significant global recession, it seems nonsense that stock markets should have gone so high – yet there seemed no signs of anything that would stop them.

But then came the news of the Omicron variant and the fear that surrounds it, which led to a massive selloff on November 26 (and a partial rebound at the time of writing). So what should we make of this? Are financial markets acknowledging that we have been in a bubble, with share prices misaligned with the real economy, or is this just a temporary panic before a continuation upwards?

What we know so far

These are the facts: new coronavirus variant B.1.1.529 spread significantly in South Africa and Botswana and was identified as more contagious and less controllable than previously known variants. Daily cases in South Africa are now nearing 3,000, which is still not much more than one-tenth of the peak reached in July. Only 24.4% of the population is vaccinated.

Cases of the Omicron variant have now been detected in many other countries, including the UK, Egypt, Belgium and Ireland. With the World Health Organization (WHO) warning that the new variant was likely to spread further and “poses a very high global risk”, many countries have closed their borders to air traffic from southern Africa. Simultaneously, the US, UK, EU, India and several other nations have implemented new restrictions on mobility and travel.

Despite the panic, Dr Angelique Coetzee – the doctor who first spotted the new variant, who also chairs the South African Medical Association – has told the BBC that symptoms linked to Omicron have been extremely mild. Meanwhile, pharmaceutical companies are analysing whether their vaccines provide safe enough protection against Omicron, though we are yet to see conclusive results in any direction.

So it could well be that, despite the faster spread of the infection, its ultimate health, social and economic impact proves negligible. We simply do not know at this point. But detecting more uncertainty than before, financial markets have reacted with panic. For example, the S&P500 tumbled 2.3% on Friday November 26 only to rise 1.1% on Monday November 29. Most markets gave up between 2% and 4%, which is a pretty substantial one-day fall.

Future dangers

What worries me most about the current economic environment is not so much the possibility that a new wave of infections pushes the beginning of the recovery even further back, but that the great uncertainty regarding the end of the pandemic hinders our ability to make decisions for the future. For example, companies are deferring important investments until the dust clears (like expanding current businesses or making acquisitions). Similarly, staff increases may be put off to avoid the risk of downsizing if the pandemic worsens again.

The real concern is that this is for reasons that are difficult to resolve in any quick timeframe: the winding road towards immunising the whole world, the lack of information about the effectiveness of the vaccine against all possible COVID variants, and the feeling that we cannot see the light at the end of the tunnel because the tunnel is longer than we thought.

It does not bode well if we compare monthly stock returns of the S&P500 in 2020 and 2021. If we exclude January and February as pre-pandemic months in most countries in 2020 (and exclude December 2021 since we don’t yet have data), it is striking to observe that 2020 was better in six out of nine months (the exceptions being March, June and September).

I remember how, back on New Year’s Eve 2020, I toasted 2021 – thinking that it could not be any worse than what we were leaving behind. But it is becoming clear that uncertainty today is even greater than a year ago, when we did even not have the vaccines that we have today.

Until we know when we will get rid of this virus and how our economies will regain strength, it will be too early to talk about recovery. So while investors and pension holders may see markets rising further into irrational territory in the weeks and months ahead, they will also be vulnerable to unpredictable lurches back down.The Conversation

About the Author:

Arturo Bris, Professor of Finance, International Institute for Management Development (IMD)

This article is republished from The Conversation under a Creative Commons license. Read the original article.

The US stock indices continue to fall amid Omicron uncertainty

by JustForex

The US stock indices are negative again as the first Omicron case in the US caused more uncertainty. Although the potential appearance of Omiсron in the United States was expected, the official announcement was enough to send the market into a decline, which had previously been quite positive. Overall, investor sentiment was dampened by new concerns over the Omicron coronavirus variant and statements by Jerome Powell that the Fed was ready to accelerate the process of reducing the stimulation program. It could mean interest rates hikes sooner than expected. The Dow Jones (US30) decreased by 1.34% by market close, the S&P 500 (US500) decreased by 1.18%, the Nasdaq (US100) lost 1.83%.

The volatility in the financial markets has been near the highest level since January. Analysts believe the volatility will persist through the end of December, driven by a tightening of central bank policy to fight inflation, while the Omicron variant threatens to prevent the recovery from the pandemic. Many questions about this strain remain unanswered.

WHO experts are increasingly convinced that the new Omicron strain is very “soft” and so far has not led to a dramatic increase in deaths anywhere, including in southern Africa.

Japan wants to stop all incoming international flights. Japan’s Ministry of Transportation is asking international airlines to stop booking all incoming flights into the country until 2022 because of the Omicron strain. The Japanese yen is at seven-week highs as investors shift their assets into safe-haven currencies. Airline stocks ended yesterday’s trading with a sharp drop. American Airlines (AAL) decreased by 8%, United Airlines Holdings Inc (UAL) lost 7.6%, and Delta Air Lines (DAL) lost 7.4%.

Amazon (AMZN) is investing in 274 renewable energy projects around the world.

European stock indexes ended yesterday’s trading with a solid gain despite rising inflation in the region as well as a rise in Covid-19 cases. French index CAC 40 (FR40) gained 2.4%, British FTSE 100 (UK100) jumped by 1.6%, German DAX (DE40) increased by 2.5%, Spanish IBEX (ES35) added 1.8%. The ECB representatives gave a clear understanding of the future monetary policy in the region. The ECB won’t reduce the PEPP program until the spring of 2022, so European stock indices will now be more resilient to shocks than US stock markets.

Turkey’s central bank intervened in the markets by selling foreign currency for the first time in seven years to stop the lira from falling against the US dollar. The intervention was due to “unhealthy pricing” in the market.

The US oil inventories fell by 909,000 barrels over the week. Oil prices increased slightly in today’s trading as investors adjust their positions ahead of the OPEC+ meeting, where the issue of production volumes will probably be considered. But analysts believe OPEC+ will decide to keep the current supply level and are confident that the growth of oil prices is limited. This is caused by concerns that the spread of the Omicron strain will negatively impact fuel demand since many countries have already closed flights.

The Central Bank of Ireland buys gold for the first time in years. The institution bought 2 tons of precious metal last month. The Irish central bank is adding to its gold reserves as inflation in the Eurozone far exceeds the European Central Bank’s target. Singapore increased its gold reserves by about 20% earlier this year. But that doesn’t mean that gold prices should rise at all. Gold has lost its status as a safe haven asset against inflation because it highly depends on US Treasury yields, which in turn depend on the Fed policy. When the QE program is cut, government bond yields rise, while making gold and silver prices fall.

Main market quotes:

S&P 500 (F) (US500) 4,513.04 −53.96 (−1.18%)

Dow Jones (US30) 34,022.04 −461.68 (−1.34%)

DAX (DE40) 15,472.67 +372.54 (+2.47%)

FTSE 100 (UK100) 7,168.68 +109.23 (+1.55%)

USD Index 96.08 +0.08 (+0.08%)

Important events for today:
  • – Australia Retail Sales (m/m) at 02:30 (GMT+2);
  • – OPEC+ Meeting at 12:00 (GMT+2);
  • – Eurozone Unemployment Rate (m/m) at 12:00 (GMT+2);
  • – US Initial Jobless Claims (w/w) at 15:30 (GMT+2);
  • – US Treasury Secretary Yellen Speaks at 16:00 (GMT+2);
  • – US Natural Gas Storage (w/w) at 17:30 (GMT+2).

by JustForex

 

This article reflects a personal opinion and should not be interpreted as an investment advice, and/or offer, and/or a persistent request for carrying out financial transactions, and/or a guarantee, and/or a forecast of future events.

5 Interesting Energy Stocks added to our Watchlist this Quarter

The fourth quarter of 2021 is approximately two-thirds over and we wanted to highlight some of the Top Energy Companies that have been analyzed by our QuantStock system so far. Our QuantStock system is a proprietary algorithm that takes into account key company fundamentals, earnings trends and other strength components to find quality companies. We use it as a stock market ideas generator and to update our stock watchlist every quarter. The QuantStock system does not take into consideration the stock price or technical price trends so one must compare each company idea against the current stock prices. There are a plethora of professional studies that continue to show stock markets are overvalued and this is always a key component to consider when researching any stock market idea. As with all investment ideas, past performance does not guarantee future results.

Here we go with 5 of our Top Energy Stocks two-thirds of the way through Quarter 4 of 2021:

Suncor Energy

Energy Stock | Medium Cap | 5.42 percent dividend | 15.22 P/E | Our Grade = C+

Suncor Energy Inc. (NYSE: SU) Energy Stock Chart

Suncor Energy Inc. (NYSE: SU) is one of Canada’s biggest energy stocks. It is an integrated energy company engaged in producing synthetic crude from oil sands. Suncor last announced its financial results for the third quarter on October 27. It came up with earnings of 56 cents per share and revenue of $8.11 billion for the three months ended September 30. The results showed significant improvement from the comparable quarter of 2020 but missed the consensus forecast of 58 cents per share for profit and $8.5 billion for revenue. Despite missing expectations, Suncor Energy stock climbed to a new high of $26.97 earlier this month.


Matador Resources Co.

Energy Stock | Small Cap | 0.51 percent dividend | 16.78 P/E | Our Grade = C-

Matador Resources Co. (NYSE: MTDR) Energy Stock Chart

Matador Resources Co. (NYSE: MTDR) is an energy company based in Texas, United States. The company last month announced impressive financial results for the third quarter. Matador earned $1.25 per share during the three months ended September 30, beating the consensus forecast of 96 cents per share. Moreover, it generated revenue of $472.351 million during the quarter, ahead of analysts’ average estimate of $387.950 million. In addition, Matador stock has also performed exceptionally well so far in 2021. The company’s share price has skyrocketed more than 200 percent on a year-to-date basis. The 52-week range of the stock is $10.16 – $47.23, while its total market value stands close to $4.5 billion.


Magnolia Oil & Gas Corp.

Energy Stock | Small Cap | 0.84 percent dividend | 11.29 P/E | Our Grade = C-

Magnolia Oil & Gas Corp. (NYSE: MGY) Energy Stock Chart

Magnolia Oil & Gas Corp. (NYSE: MGY) is another Texas-based oil producer. The company posted solid financial results for the third quarter earlier this month. Magnolia reported adjusted earnings of 67 cents per share on revenue of $283.58 million. The results easily surpassed analysts’ average estimate of 61 cents per share for earnings and $274 million for revenue. If we quickly look at its key financial metrics, Magnolia stock is currently trading around $18.82, against its 52-week range of $18.38 – $19.07. Moreover, the company’s market value is just over $3.4 billion, while its P/E ratio stands at 11.03.


China Petroleum & Chemical Corp.

Energy Stock | Medium Cap | 10.26 percent dividend | 3.71 P/E | Our Grade = C

China Petroleum & Chemical Corporation (NYSE: SNP) Energy Stock Chart

China Petroleum & Chemical Corporation (NYSE: SNP), commonly known as Sinopec, is a leading oil and gas company based in China. Besides its listing in the New York Stock Exchange, it also trades in Hong Kong and Shanghai. Sinopec last month announced mixed results for the third quarter. Its reported earnings of $2.64 per share, representing a sharp decline from $5.54 per share in the comparable period of 2020. On the positive side, its revenue for the third quarter grew over 52 percent to $114.58 million. If we look at its share price, Sinopec stock has struggled to gain value so far in 2021. The stock has only increased nearly one percent on a year-to-date basis.


Petróleo Brasileiro S.A.

Energy Stock | Medium Cap | 19.49 percent dividend | 2.71 P/E | Our Grade = C

Petróleo Brasileiro S.A. (NYSE: PBR) Energy Stock Chart

Petróleo Brasileiro S.A. (NYSE: PBR) is one of the leading energy stocks based in Rio de Janeiro, Brazil. The company, also called Petrobras, is engaged in the exploration and production of oil and natural gas. Petrobras last released its quarterly financial results on October 28. The company reported earnings of $5.9 billion for the third quarter, down 26.9 percent from Q2 but significantly higher than the comparable period of 2020. In addition, its quarterly revenue of $23.3 billion was also well above $13.15 billion in the year-ago period. If we talk about its share price movement, Petrobras stock hasn’t performed well this year. The stock is still down nearly six percent on a year-to-date basis.


Article by InvestMacro – Be sure to join our stock market newsletter to get our updates and to see more top companies we add to our stock watch list.

 

AAPL Is The Ending Diagonal Not Complete Yet?

By Orbex

AAPL

AAPL shares seem to be forming a primary fifth wave, taking the form of an ending diagonal of the intermediate degree (1)-(2)-(3)-(4)-(5). This wave is also the final one in the cycle impulse a.

It is likely that at the moment we are in the intermediate wave (3). This wave is taking the form of a double combination W-X-Y. An actionary wave Y is necessary to complete the specified pattern.

Bulls in the minor wave Y can send the market to the level of 174.48, which is on the resistance line. And then the price could fall within the correction (4) to the support level of 138.14, as shown on the chart.

AAPL

An alternative scenario suggests that the ending diagonal has fully completed its pattern, and the cycle impulse wave a has also come to an end.

If that is the case, then in the upcoming trading weeks market participants will see a collapse in prices in a cycle correction b. This correction may take the form of a standard zigzag Ⓐ-Ⓑ-Ⓒ.

There is a high probability that the bears will be able to bring the market to the previous low of -115.79, where the primary fourth correction ended earlier.


Orbex-LogoArticle by Orbex

Orbex is a fully licensed broker that was established in 2011. Founded with a mission to serve its traders responsibly and provides traders with access to the world’s largest and most liquid financial markets. www.orbex.com